Cargando...
Invasive procedures in patients undergoing treatment with lenvatinib for thyroid cancer
Lenvatinib is a multi-tyrosine kinase inhibitor that inhibits angiogenesis and is currently in use for the treatment of refractory thyroid cancer. Therapy using this agent can be prolonged in patients, although serious complications may ensue among those who require surgical procedures. To the best...
Guardado en:
| Publicado en: | Mol Clin Oncol |
|---|---|
| Autores principales: | , , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
D.A. Spandidos
2021
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7947953/ https://ncbi.nlm.nih.gov/pubmed/33758662 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2021.2243 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|